KZR - Kezar Life Sciences, Inc.

6.94
0.110   1.585%

Share volume: 26,421
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$6.83
0.11
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.25%
1 Month
12.85%
3 Months
10.51%
6 Months
73.07%
1 Year
20.49%
2 Year
625.56%
Key data
Stock price
$6.94
P/E Ratio 
0.00
DAY RANGE
$6.63 - $7.02
EPS 
-$8.44
52 WEEK RANGE
$3.53 - $7.45
52 WEEK CHANGE
$20.49
MARKET CAP 
28.560 M
YIELD 
N/A
SHARES OUTSTANDING 
7.323 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$46,558
AVERAGE 30 VOLUME 
$56,056
Company detail
CEO: John Fowler
Region: US
Website: kezarlifesciences.com
Employees: 60
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.

Recent news